Browse News
Filter News
Found 13,321 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
10/3/2023
Ocean Biomedical, Inc. announced that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor mutations.
-
A Quarter Century of Disease-Focused Neuroscience
10/3/2023
A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease.
-
Compugen to Present at Single Cell Genomics 2023 Meeting
10/3/2023
Compugen Ltd. today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.
-
Judge Michael Newman of the Southern District of Ohio issued a ruling Friday denying the U.S. Chamber of Commerce’s request for a preliminary injunction against the Inflation Reduction Act provisions.
-
Keep up with the regulator's latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
10/2/2023
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.
-
Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms
10/2/2023
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today shared the results of an exploratory analysis evaluating the effects of patient characteristics on baseline vaginal/vulvar symptoms during its Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1) study.
-
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
10/2/2023
Aura Biosciences Inc. announced the appointments of Jill Hopkins, M.D., as Chief Medical Officer, President of Research & Development, and Mark Plavsic, Ph.D., as Chief Technology Officer.
-
Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer
10/2/2023
Sermonix Pharmaceuticals today shared the results of EQUALS 2 (ESR1 QUAlity of Life Survey 2), a survey on the vaginal and sexual health of patients with ER+/HER2- metastatic breast cancer.
-
Non-small cell lung cancer patients treated with the drug combination saw a statistically significant and clinically meaningful improvement in progression-free survival compared to AstraZeneca’s osimertinib.
-
Peptone Expands Leadership Team with Key Executive Hires
9/28/2023
Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins, announced the appointment of key leaders to its Executive Management Team and Board of Directors.
-
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
9/28/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that The Journal of the American Medical Association (JAMA) published positive results from the Phase 3 NEURO-TTRansform study of eplontersen, an investigational treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
-
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
9/28/2023
BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody targeting the T cell immunoglobulin and mucin domain-containing protein 3, also known as TIM-3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI for the treatment of advanced hepatocellular carcinoma.
-
Despite filing respective lawsuits challenging the program, AstraZeneca and Bristol Myers Squibb have decided to participate in the first round of price negotiations under the Inflation Reduction Act.
-
While Astellas did not say why it withdrew its suit, it was the only company to file a legal complaint that wasn’t on the initial IRA drug price negotiations list and may not have had any grounds to sue.
-
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
9/27/2023
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA.
-
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
9/26/2023
Ambrx Biopharma Inc., Ambrx, announced that it will host an in-person key opinion leader event during the European Society for Medical Oncology Congress 2023.
-
Ligand Appoints Martine Zimmermann to its Board of Directors
9/26/2023
Ligand Pharmaceuticals Incorporated announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director.
-
Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure
9/26/2023
Revvity, Inc., unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.